488
Views
25
CrossRef citations to date
0
Altmetric
Review

Comprehensive grading of Parkinson’s disease using motor and non-motor assessments: addressing a key unmet need

&
Pages 41-50 | Received 15 Sep 2017, Accepted 31 Oct 2017, Published online: 07 Nov 2017

References

  • Chaudhuri KR, Odin P, Antonini A, et al. Parkinson’s disease: the non-motor issues. Parkinsonism Relat Disord. 2011;17:717–723.
  • Jellinger K. Neuropathobiology of non-motor symptoms in Parkinson disease. J Neural Transm (Vienna). 2015;122:1429–1440.
  • Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013.
  • Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017;18:435–450.
  • Titova N, Padmakumar C, Lewis S, et al. Parkinson’s: a syndrome rather than a disease? J Neural Transm. 2017;124:907–914.
  • Titova N, Chaudhuri KR. Personalised medicine in Parkinson’s disease: time to be precise. Mov Disord. 2017;32:1147–1154.
  • Schrag A, Horsfall L, Walters K, et al. Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study. Lancet Neurol. 2015;14:57–64.
  • Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8:464–474.
  • Postuma RB, Aarsland D, Barone P, et al. Identifying prodromal Parkinson’s disease: pre-motor disorders in Parkinson’s disease. Mov Disord. 2012;27:617–626.
  • Stern MB, Lang A, Poewe W. Toward a redefinition of Parkinson’s disease. Mov Disord. 2012;27:54–60.
  • Berg D, Postuma RB, Adler CH, et al. MDS research criteria for prodromal Parkinson’s disease. Mov Disord. 2015;30:1600–1611.
  • Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1988;51:745–752.
  • Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386:896–912.
  • Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30:1591–1601.
  • Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson’s disease. A community-based study. Brain. 2000;123:2297–2305.
  • Lopez IC, Ruiz PJ, Del Pozo SV, et al. Motor complications in Parkinson’s disease: ten year follow-up study. Mov Disord. 2010;25:2735–2739.
  • Storch A, Schneider CB, Wolz M, et al. Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology. 2013;80:800–809.
  • Aquino CC, Fox SH. Clinical spectrum of levodopa-induced complications. Mov Disord. 2015;30:80–89.
  • Aarsland D, Creese B, Politis M, et al. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017;13:217–231.
  • Bjornestad A, Pedersen KF, Tysnes O-B, et al. Clinical milestones in Parkinson’s disease: a 7-year population-based incident cohort study. Parkinsonism Relat Disord. 2017;42:28–33.
  • Hanagasi HA, Tufekcioglu Z, Emre M. Dementia in Parkinson’s disease. J Neurol Sci. 2017;374:26–31.
  • Chaudhuri KR, Schapira AHV, Martínez-Martín P, et al. Can we improve the holistic assessment of Parkinson’s disease? The development of a non-motor symptom questionnaire and scale for Parkinson’s disease. ACNR. 2004;4:20–25.
  • Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord. 2006;21(7):916–923.
  • Chaudhuri KR, Martinez-Martin P, Brown RG, et al. The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov Disord. 2007;22:1901–1911.
  • Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, et al. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov Disord. 2011;26:399–406.
  • Kadastik-Eerme L, Rosenthal M, Paju T, et al. Health-related quality of life in Parkinson’s disease: a cross-sectional study focusing on non-motor symptoms. Health Qual Life Outcomes. 2015;13:83.
  • Skorvanek M, Rosenberger J, Minar M, et al. Relationship between the non-motor items of the MDS-UPDRS and Quality of Life in patients with Parkinson’s disease. J Neurol Sci. 2015;353:87–91.
  • Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23:837–844.
  • Martinez-Martin P, Rodriguez-Blazquez C, Paz S, et al. Parkinson symptoms and health related quality of life as predictors of costs: a longitudinal observational study with linear mixed model analysis. PLoS One. 2015;10:e0145310.
  • Hassan A, Wu SS, Schmidt P, et al. The profile of long-term Parkinson’s disease survivors with 20 years of disease duration and beyond. J Parkinsons Dis. 2015;5:313–319.
  • Puschmann A, Brighina L, Markopoulou K, et al. Clinically meaningful parameters of progression and long-term outcome of Parkinson disease: an international consensus statement. Parkinsonism Relat Disord. 2015;21:675–682.
  • Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, et al. The nondeclaration of nonmotor symptoms of Parkinson’s disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord. 2010;25:704–709.
  • Ray Chaudhuri K, Rojo JM, Schapira AH, et al. A proposal for a comprehensive grading of Parkinson’s disease severity combining motor and non-motor assessments: meeting an unmet need. PLoS One. 2013;8:e57221.
  • Chaudhuri KR, Sauerbier A, Rojo JM, et al. The burden of non-motor symptoms in Parkinson’s disease using a self-completed non-motor questionnaire: a simple grading system. Parkinsonism Relat Disord. 2015;21:287–291.
  • Collins English Dictionary. [cited 2017 Jul 28]. Available from: https://www.collinsdictionary.com/dictionary/english/grading.
  • Guy W, editor. ECDEU assessment manual for psychopharmacology. Rockville (MD): US Department of Health, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration; 1976. p. 217–222.
  • Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4:28–37.
  • Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med. 1999;340:757–763.
  • Martinez-Martin P, Benito-Leon J, Burguera JA, et al. The SCOPA-Motor Scale for assessment of Parkinson’s disease is a consistent and valid measure. J Clin Epidemiol. 2005;58:674–679.
  • Fernandez HH, Aarsland D, Fénelon G, et al. Scales to assess psychosis in Parkinson’s disease: critique and recommendations. Mov Disord. 2008;23:484–500.
  • Goetz CG, Stebbins GT, Chung KA, et al. Which dyskinesia scale best detects treatment response? Mov Disord. 2013;28:341–346.
  • Martinez-Martin P, Rodriguez-Blazquez C, Alvarez M, et al. Parkinson’s disease severity levels and MDS-Unified Parkinson’s Disease Rating Scale. Parkinsonism Relat Disord. 2015;21:50–54.
  • Okai D, Askey-Jones S, Samuel M, et al. Predictors of response to a cognitive behavioral intervention for impulse control behaviors in Parkinson’s disease. Mov Disord. 2015;30:736–739.
  • Martinez-Martin P, Rojo-Abuin JM, Rodriguez-Violante M, et al. Analysis of four scales for global severity evaluation in Parkinson’s disease. NPJ Parkinsons Dis. 2016;2:16007.
  • Bump RC, Norton PA, Zinner NR, et al. Mixed urinary incontinence symptoms: urodynamic findings, incontinence severity, and treatment response. Obstet Gynecol. 2003;102:76–83.
  • Targum SD, Hassman H, Pinho M, et al. Development of a clinical global impression scale for fatigue. J Psychiatr Res. 2012;46:370–374.
  • Agüera-Ortiz L, Montón C, Cuervo J, et al. Adaptation into Spanish of the Clinically Useful Depression Outcome Scale (CUDOS) for assessing major depressive disorder from the patient’s perspective. Actas Esp Psiquiatr. 2013;41:287–300.
  • Fernandez HH, Jankovic J, Holds JB, et al. Observational study of incobotulinumtoxinA for cervical dystonia or blepharospasm (XCiDaBLE): interim results for the first 170 subjects with blepharospasm. Tremor Other Hyperkinet Mov (N Y). 2014;4:238.
  • Ambrosio L, Portillo MC, Rodriguez-Blazquez C, et al. Satisfaction with Life Scale (SLS-6): first validation study in Parkinson’s disease population. Parkinsonism Relat Disord. 2016;25:52–57.
  • Titova N, Qamar MA, Chaudhuri KR. Biomarkers of Parkinson’s disease: an introduction. Int Rev Neurobiol. 2017;132:183–193.
  • Simuni T, Luo ST, Chou KL, et al. Rankin scale as a potential measure of global disability in early Parkinson’s disease. J Clin Neurosci. 2013;20:1200–1203.
  • Pistacchi M, Gioulis M, Sanson F, et al. Gait analysis and clinical correlations in early Parkinson’s disease. Funct Neurol. 2017;32:28–34.
  • Khoo TK, Yarnall AJ, Duncan GW, et al. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology. 2013;80:276–281.
  • Erro R, Picillo M, Vitale C, et al. Non-motor symptoms in early Parkinson’s disease: a 2-year follow-up study on previously untreated patients. J Neurol Neurosurg Psychiatry. 2013;84:14–17.
  • Ongre SO, Larsen JP, Tysnes OB, et al. Fatigue in early Parkinson’s disease: the Norwegian ParkWest study. Eur J Neurol. 2017;24:105–111.
  • Pahwa R, Lyons KE, Hauser RA, et al. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson’s disease. Parkinsonism Relat Disord. 2014;20:142–148.
  • Zis P, Erro R, Walton CC, et al. The range and nature of non-motor symptoms in drug-naive Parkinson’s disease patients: a state-of-the-art systematic review. NPJ Parkinsons Dis. 2015;1:15013.
  • Duncan GW, Khoo TK, Yarnall AJ, et al. Health-related quality of life in early Parkinson’s disease: the impact of nonmotor symptoms. Mov Disord. 2014;29:195–202.
  • Giladi N, Asgharnejad M, Bauer L, et al. Rotigotine in combination with the MAO-B inhibitor selegiline in early Parkinson’s disease: a post hoc analysis. J Parkinsons Dis. 2016;6:401–411.
  • Luquin MR, Kulisevsky J, Martinez-Martin P, et al. Consensus on the definition of advanced Parkinson’s disease: a neurologists-based Delphi study (CEPA study). Parkinsons Dis. 2017;2017:4047392.
  • Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427–442.
  • Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23:2129–2170.
  • Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004;19:1020–1028.
  • Martínez-Martín P, Gil-Nagel A, Gracia LM, et al. Unified Parkinson’s Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group. Mov Disord. 1994;9:76–83.
  • Piccini P, Pavese N, Canapicchi R, et al. White matter hyperintensities in Parkinson’s disease. Clinical correlations. Arch Neurol. 1995;52:191–194.
  • Schrag A, Selai C, Jahanshahi M, et al. The EQ-5D–a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2000;69:67–73.
  • Marinus J, Visser M, Stiggelbout AM, et al. A short scale for the assessment of motor impairments and disabilities in Parkinson’s disease: the SPES/SCOPA. J Neurol Neurosurg Psychiatry. 2004;75:388–395.
  • Martinez-Martin P, Prieto L, Forjaz MJ. Longitudinal metric properties of disability rating scales for Parkinson’s disease. Value Health. 2006;9:386–393.
  • Thannickal TC, Lai Y-Y, Siegel JM. Hypocretin (orexin) cell loss in Parkinson’s disease. Brain. 2007;130:1586–1595.
  • Maetzler W, Liepelt I, Berg D. Progression of Parkinson’s disease in the clinical phase: potential markers. Lancet Neurol. 2009;8:1158–1171.
  • Yagi S, Yoshikawa E, Futatsubashi M, et al. Progression from unilateral to bilateral parkinsonism in early Parkinson disease: implication of mesocortical dopamine dysfunction by PET. J Nucl Med. 2010;51:1250–1257.
  • Martinez-Martin P, Rodriguez-Blazquez C, Alvarez-Sanchez M, et al. Expanded and independent validation of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). J Neurol. 2013;260:228–236.
  • Rodriguez-Blazquez C, Rojo-Abuin JM, Alvarez-Sanchez M, et al. The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson’s disease. Parkinsonism Relat Disord. 2013;19:889–893.
  • Hsiao IT, Weng YH, Hsieh CJ, et al. Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography. JAMA Neurol. 2014;71:758–766.
  • Yildiz D, Erer S, Zarifoğlu M, et al. Impaired cognitive performance and hippocampal atrophy in Parkinson disease. Turk J Med Sci. 2015;45:1173–1177.
  • Wu G, Shen Y-J, Huang M-H, et al. Proton MR Spectroscopy for monitoring pathologic changes in the substantia nigra and globus pallidus in Parkinson disease. AJR Am J Roentgenol. 2016;206:385–389.
  • Skorvanek M, Martinez-Martin P, Kovacs N, et al. Differences in MDS-UPDRS scores based on Hoehn and Yahr stage and disease duration. Mov Disord-Clin Practice. 2017;4:536–544.
  • Sauerbier A, Qamar MA, Rajah T, et al. New concepts in the pathogenesis and presentation of Parkinson’s disease. Clin Med (Lond). 2016;16:365–370.
  • Martinez-Martin P, Forjaz MJ, Cubo E, et al. Global versus factor-related impression of severity in Parkinson’s disease: a new clinimetric index (CISI-PD). Mov Disord. 2006;21:208–214.
  • Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ, et al. The clinical impression of severity index for Parkinson’s disease: international validation study. Mov Disord. 2009;24:211–217.
  • Armañanzas R, Bielza C, Chaudhuri KR, et al. Unveiling relevant non-motor Parkinson’s disease severity symptoms using a machine learning approach. Artif Intell Med. 2013;58:195–202.
  • Martinez-Martin P, Rodriguez-Blazquez C, Abe K, et al. International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease. Neurology. 2009;73:1584–1591.
  • Martinez-Martin P, Falup Pecurariu C, Odin P, et al. Gender-related differences in the burden of non-motor symptoms in Parkinson’s disease. J Neurol. 2012;259:1639–1647.
  • Martinez-Martin P, Chaudhuri KR, Rojo-Abuin JM, et al. Assessing the non-motor symptoms of Parkinson’s disease: MDS-UPDRS and NMS scale. Eur J Neurol. 2015;22:37–43.
  • Martinez-Martin P, Reddy P, Katzenschlager R, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease. Mov Disord. 2015;30:510–516.
  • Dafsari HS, Reddy P, Herchenbach C, et al. Beneficial effects of bilateral subthalamic stimulation on non-motor symptoms in Parkinson’s disease. Brain Stimul. 2016;9:78–85.
  • Kurtis MM, Rajah T, Delgado LF, et al. The effect of deep brain stimulation on the non-motor symptoms of Parkinson’s disease: a critical review of the current evidence. NPJ Parkinsons Dis. 2017;3:16024.
  • Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–174.
  • Martinez-Martin P, Schapira AH, Stocchi F, et al. Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord. 2007;22:1623–1629.
  • Rodríguez-Violante M, Cervantes-Arriaga A, Villar-Velarde A, et al. Prevalence of non-motor dysfunction among Parkinson’s disease patients from a tertiary referral center in Mexico City. Clin Neurol Neurosurg. 2010;112:883–885.
  • Crosiers D, Pickut B, Theuns J, et al. Non-motor symptoms in a Flanders-Belgian population of 215 Parkinson’s disease patients as assessed by the Non-Motor Symptoms Questionnaire. Am J Neurodegener Dis. 2012;1:160–167.
  • National Institute of Clinical Excellence (NICE). Parkinson’s disease in adults. NICE guidelines, Published 19 July 2017. 23 p. Available from: Nice.org.uk/guidance/ng71.
  • Fahn S, Elton RL; Members of the UPDRS Development Committee. Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Calne DB, et al., editors. Recent developments in Parkinson’s disease. Vol. 2. Florham Park (NJ): Macmillan Healthcare Information; 1987. p. 153–164.
  • Movement Disorder Society Task Force on Rating Scales for Parkinson’s disease. UPDRS: status and recommendations. Mov Disord. 2003;18:738–750.
  • Antonini A, Abbruzzese G, Ferini-Strambi L, et al. Validation of the Italian version of the Movement Disorder Society—Unified Parkinson’s Disease Rating Scale. Neurol Sci. 2013;34:683–687.
  • Goetz CG, Stebbins GT, Wang L, et al. IPMDS-sponsored scale translation program: process, format, and clinimetric testing plan for the MDS-UPDRS and UDysRS. Mov Disord Clin Pract. 2014;1:97–101.
  • International Parkinson and Movement Disorder Society. [ cited 2017 Aug 11]. Available from: http://www.movementdisorders.org/MDS/Education/Rating-Scales.htm.
  • Verbaan D, Van Rooden SM, Benit CP, et al. SPES/SCOPA and MDS-UPDRS: formulas for converting scores of two motor scales in Parkinson’s disease. Parkinsonism Relat Disord. 2011;17:632–634.
  • Gallagher DA, Goetz CG, Stebbins G, et al. Validation of the MDS-UPDRS Part I for nonmotor symptoms in Parkinson’s disease. Mov Disord. 2012;27:79–83.
  • Goetz CG, Stebbins GT, Tilley BC. Calibration of unified Parkinson’s disease rating scale scores to movement disorder society-unified Parkinson’s disease rating scale scores. Mov Disord. 2012;27:1239–1242.
  • Stebbins GT, Goetz CG, Burn DJ, et al. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson’s disease rating scale: comparison with the unified Parkinson’s disease rating scale. Mov Disord. 2013;28:668–670.
  • Martínez-Martín P, Rodríguez-Blázquez C, Forjaz MJ, et al. Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson’s disease patients. Eur J Neurol. 2014;21:519–524.
  • Jafari N, Pahwa R, Nazzaro JM, et al. MDS-UPDRS to assess non-motor symptoms after STN DBS for Parkinson’s disease. Int J Neurosci. 2016;126:25–29.
  • SCOPA scales. [ cited 2017 Oct 18]. Available from: https://www.lumc.nl/org/neurologie/research/propark-research/Scales/?setlanguage=English&setcountry=en.
  • Ba F, Obaid M, Wieler M, et al. Parkinson disease: the relationship between non-motor symptoms and motor phenotype. Can J Neurol Sci. 2016;43:261–267.
  • Fereshtehnejad S-M, Postuma RB. Subtypes of Parkinson’s disease: what do they tell us about disease progression? Curr Neurol Neurosci Rep. 2017;17:34.
  • Marras C, Chaudhuri KR. Nonmotor features of Parkinson’s disease subtypes. Mov Disord. 2016;31:1095–1102.
  • Mu J, Chaudhuri KR, Bielza C, et al. Parkinson’s disease subtypes identified from cluster analysis of motor and non-motor symptoms. Front Aging Neurosci. 2017;20;9:301.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.